Initiated preparation of AST-301 (therapeutic cancer vaccine) Phase 2 IND application
Established a strategic partnership with EpiThany Inc. (USA)
Apr
Initiated non-clinical studies of AST-021p & 023 (therapeutic cancer vaccine)
Jul
Initiated the development of AST-05X
Certified as a Venture Business
Nov
Completed Series A funding
2020
Jun
Initiated the development of AST-51X
Jul
Signed an agreement with Pinotbio to conduct collaborative clinical development of AST-081
Aug
Submitted IND application for AST-021p
Submitted IND application for AST-301
Oct
Relocated headquarters to Daechi-dong, Gangnam, Seoul
Nov
Completed Series B funding
2021
Jan
Established Aston Sci. Inc. R&D facility in Gwanggyo
Feb
IND approval granted for AST-021p Phase 1 clinical trial in Korea (by MFDS)
Mar
Signed a technology transfer agreement with CVI (licensor) for an adjuvant immunotherapy for cancer therapeutic vaccine
Sept
Relocated Aston Sci. Inc. R&D Facility to Hanam City
Nov
Presented the study results of two therapeutic cancer vaccines (AST-301 and AST-021p) at the 2021 Society for Immunotherapy of Cancer (SITC)
Dec
Aston Sci. Inc. and KU Research & Business Foundation signed technology transfer agreement
Completed Series C funding
2022
Feb
IND approval granted for AST-301 Phase 2 clinical trial in Australia (by TGA) for HER2-low breast cancer patients
Apr
IND approval granted for AST-301 Phase 2 clinical trial in Taiwan (by TFDA) for HER2-low breast cancer patients
Jun
Signed an MoU with Reyon Pharmaceutical Co., Ltd. on cooperation in the field of research and development for pDNA cancer vaccines
Jul
Filed a patent application for Th-Vac™ Platform (Epitope-based therapeutic vaccine design platform technology)
Aug
IND approval granted for AST-301 Phase 2 clinical trial in the U.S. (by FDA) for HER2-low breast cancer patients
Dec
Signed an MoU with GeneOne Life Science on cooperation in the field of research and development for mRNA vaccines
Presented the Phase 1 result of AST-302 (WOKVAC) at San Antonio Breast Cancer Symposium (SABCS)
2023
Apr
Presented the study results of two therapeutic cancer vaccines (AST-301 and AST-021p) at the American Association for Cancer Research (AACR) Annual Meeting 2023
May
IND approval granted for AST-301 Phase 2 clinical trial in Taiwan (by TFDA) for HER2-positive gastric cancer patients
IND approval granted for AST-201 Phase 2 clinical trial in the U.S. (by FDA) for ovarian cancer patients
Nov
Signed an exclusive research and license agreement with Abogen Biosciences for global therapeutic cancer vaccine development
Presented five posters on cancer vaccine research at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2023
Dec
Selected to advance a research and development project in the 2024 Industry-Academia Collaborative New Drug Development Program, targeting the development of a treatment for epilepsy
2024
Apr
Presented six research findings including the phase 1 clinical trial results of the cancer vaccine AST-021p at the American Association for Cancer Research (AACR) Annual Meeting 2024
